Ustekinumab (UST) — Competitive Intelligence Brief

Ustekinumab (UST) (Ustekinumab (UST)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-12/IL-23 inhibitor monoclonal antibody. Area: Immunology.

marketed IL-12/IL-23 inhibitor monoclonal antibody IL-12 p40 / IL-23 p40 subunit Immunology Small molecule

Target snapshot

Ustekinumab (UST) (Ustekinumab (UST)) — Second Affiliated Hospital, School of Medicine, Zhejiang University. Ustekinumab is a monoclonal antibody that blocks the IL-12 and IL-23 signaling pathways by binding to their shared p40 subunit, reducing inflammatory immune responses.

Comparator set (1 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ustekinumab (UST) TARGET	Ustekinumab (UST)	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	IL-12/IL-23 inhibitor monoclonal antibody	IL-12 p40 / IL-23 p40 subunit
Ustekinumab SC	Ustekinumab SC	Janssen Research & Development, LLC	phase 3	IL-12/IL-23 inhibitor monoclonal antibody	IL-12/IL-23 p40 subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-12/IL-23 inhibitor monoclonal antibody class)

1. Janssen Research & Development, LLC · 1 drug in this class
2. Second Affiliated Hospital, School of Medicine, Zhejiang University · 1 drug in this class